Corey Langer, MD
As we embark on a third year of practice and research during an ever-evolving, seemingly ceaseless pandemic, we know there will be more changes and challenges in store for the field of thoracic oncology.
We welcome the rapid deployment of scientific advances and are grateful for how these advances have expanded our treatment options and informed our treatment decisions, but we realize that simply staying up to date on the latest research is a major challenge when time is in short supply.
With that in mind, one thing that won’t change in 2022 is the timely and relevant insights you’ve come to count on from IASLC Lung Cancer News. ILCN may look a little different this year—and will now come to you twice a month—but the high quality of the content will continue.
Our editorial group includes experts in thoracic oncology from around the globe dedicated to bringing diverse voices and understanding to discussions about the latest advances in the field. This team has put together a provocative collection of articles for our first email issue of 2022.
Keep reading for ongoing coverage of key presentations from scientific meetings, a Q&A with Harvard Associate Professor Lynette M. Sholl, MD, on high sensitivity of plasma cell-free DNA genotyping in cases with evidence of adequate tumor content, and part one of a two-part exploration of the art and science of patient-provider communication.
As always, we look forward to hearing from readers.
Please email us at [email protected] with any feedback or suggestions for future topics.
Thank you and Happy New Year!
Corey Langer, MD
Editor, ILCN
